Major Depressive Disorder in Long COVID and Exposure to Pro‐Inflammatory Cytokines During Infection by SARS‐CoV‐2
Identifying elevated pro-inflammatory cytokines during COVID-19 as a risk factor for MDD and severe outcomes underscores the need for early screening and targeted treatments in long COVID. Monitoring cytokine levels may help clinicians predict and manage TRD and SI/SB in this population, improving long-term psychiatric outcomes.
Authors
- Angela T.H. Kwan (ORCID: https://orcid.org/0000-0003-4013-1112)
- Juan F. Gálvez‐Flórez
- Sergio Moreno (ORCID: https://orcid.org/0000-0002-3043-0963)
- Juan‐Manuel Anaya (ORCID: https://orcid.org/0000-0002-6444-1249)
- Hernan Felipe Guillen-Burgos (ORCID: https://orcid.org/0000-0003-1835-431X)
- Roger S. McIntyre (ORCID: https://orcid.org/0000-0003-4733-2523)
- Sabrina Wong (ORCID: https://orcid.org/0009-0002-0928-3433)
- Mariana Ramirez‐Posada
Institutions
- University Health Network (CA)
- University of Ottawa (CA)
- Universidad de Los Andes (CO)
- University of Toronto (CA)
- Universidad El Bosque (CO)
- Pontificia Universidad Javeriana (CO)
- University of the Coast (CO)
- Brain and Cognition Discovery Foundation (CA)
- Universidad Simón Bolívar (CO)
- Colombian Association of Surgery (CO)
Publication Details
- Journal
- Psychiatric Research and Clinical Practice
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1176/appi.prcp.20240112
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00